Fabian Gerlinghaus, Alexander Seyf, and Knut Steffensen go behind the headlines and dive into the advanced therapy ecosystem.

Genmab A/S ADS has a trailing 12 month Price to Earnings (P/E) ratio of 12.7 while the S&P 500 average is 29.3 Its forward ...

In this week’s edition of InnovationRx, we look at the dangers of RFK Jr.’s vaccine advisory committee, how Trump’s visa ban ...

Following a disappointing performance from the company’s CAR-T candidate in an early-stage cancer trial, BioNTech is winding down cell therapy manufacturing at its inaugural U.S. plant. | Following a ...

Another patient has died from acute liver failure after receiving Sarepta’s gene therapy for DMD ; After a quiet start to the ...

BioNTech said in 2022 that it faced “threats of a groundless patent infringement suit” from a company that was “unable to ...

The latest health news covers FDA's extended review of KalVista's drug, UroGen's new bladder cancer treatment approval, ...

BioNTech announces CureVac acquisition for $1.25 billion in stock to strengthen cancer therapy pipeline and mRNA technology ...

BioNTech is acquiring CureVac in a deal that brings messenger RNA manufacturing capability and cancer immunotherapy ...

Plus: Oracle posts strong quarterly results boosted by the company's artificial-intelligence investments. Biotech company BioNTech acquires CureVac. Adobe raises its full-year outlook after posting ...

Three years after litigation started over technology used in an mRNA vaccine for COVID-19, Biontech SE is acquiring its ...

Key developments in US health news include the release of new dietary guidelines, FDA approvals for bladder and lung cancer drugs, and significant policy shifts by U.S. Health Secretary Robert F.